Anti–GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) by Taylor, PC, Weinblatt, M, McInnes, IB, Atsumi, T, Strand, V, Takeuchi, T, Bracher, M, Brooks, D, Davies, J, Goode, C, Gupta, A, Mukherjee, S, O’Shea, C, Saurigny, D, Schifano, L, Shelton, C, Smith, JE, Wang, M, Wang, R, Watts, S, Fleischmann, R

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomise... by Fleischmann, R, van der Heijde, D, Strand, V, Atsumi, T, McInnes, IB, Takeuchi, T, Taylor, PC, Bracher, M, Brooks, D, Davies, J, Goode, C, Gupta, A, Mukherjee, S, O’Shea, C, Saurigny, D, Schifano, L, Shelton, C, Smith, JE, Wang, M, Wang, R, Watts, S, Weinblatt, M